**Anlon Healthcare IPO: Unveiling a New Opportunity in Pharma Intermediates**

A Deep Dive into the Upcoming Public Offering from a Growing Pharmaceutical Sector Player

**Exploring Anlon Healthcare: The Business Core**

Anlon Healthcare Ltd., established in 2013, stands as a notable chemical manufacturing company specializing in high-purity Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). These critical components are foundational to various applications, from life-saving medicines to nutraceuticals, personal care, and even animal health products. The company's commitment to quality is evident in its adherence to Indian and international pharmacopeia standards (IP, BP, EP, JP, USP).

Beyond standard manufacturing, Anlon Healthcare offers custom manufacturing solutions for complex chemicals, consistently surpassing purity benchmarks to meet precise customer specifications. Their robust R&D capabilities and stringent quality control, supported by four dedicated labs and a team of 34 professionals, including 24 science graduates, ensure product excellence.

**Product Spectrum & Innovation:**

• **Pharma Intermediates:** Essential starting materials or advanced intermediates for API production, such as Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine.
• **Active Pharmaceutical Ingredients (APIs):** The core therapeutic components in diverse pharmaceutical products (tablets, capsules, ointments, syrups), as well as nutraceuticals, personal care, and veterinary items.
• **Global Reach:** The company boasts Drug Master File (DMF) approvals from international regulatory bodies like ANVISA, NMPA, and PMDA for key APIs like loxoprofen sodium dihydrate and loxoprofen acid. With 21 DMFs filed globally and more in the pipeline, Anlon Healthcare demonstrates strong international aspirations and regulatory compliance.

**Key Investment Highlights: Anlon Healthcare Public Offering**

Anlon Healthcare is launching a significant public offering to fuel its growth ambitions. Here’s a snapshot of the IPO details:

**Investment Tiers: Lot Size Details**

Investors interested in the Anlon Healthcare IPO can bid for a minimum of 164 shares and in multiples thereafter. The investment requirements vary for different investor categories:

**Investment Allocation: Categorical Breakdown**

The issue has defined reservation percentages for various investor categories:

• **Qualified Institutional Buyers (QIBs):** Not less than 75% of the Net Issue
• **Non-Institutional Investors (NIIs):** Not less than 15% of the Net Issue
• **Retail Individual Investors (RIIs):** Not more than 10% of the Net Issue

**Growth Trajectory: A Financial Overview**

Anlon Healthcare has demonstrated strong financial performance, particularly in the most recent fiscal year. The company's revenue and profitability have shown impressive growth, indicating operational efficiency and market expansion.

Notably, between FY 2024 and FY 2025, Anlon Healthcare's revenue surged by 81%, and its Profit After Tax (PAT) impressively climbed by 112%. This indicates strong operational momentum and effective management strategies.

**Performance Snapshot: Key Financial Metrics**

Analyzing key performance indicators provides deeper insights into the company's efficiency and financial health (as of March 31, 2025):

**Valuation at a Glance:**

Based on the latest financial figures as of March 31, 2025, and the pre-issue shareholding:

• **Pre-IPO EPS:** ₹5.15
• **Pre-IPO P/E Ratio:** 17.67x
• **Post-IPO EPS:** ₹3.86
• **Post-IPO P/E Ratio:** 23.57x

**Leadership & Ownership: Promoter Stake**

The company is promoted by Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia. Their collective holding prior to the issue stands at **70.26%**, reflecting a significant commitment from the founding team.

**Purpose of the Public Offering: Anlon Healthcare's Objectives**

The net proceeds from this issue are strategically earmarked to support the company's growth and financial stability. The key objectives include:

• **Expansion Capital Expenditure:** ₹30.72 Crores will be utilized to fund capital expenditure requirements for proposed expansion initiatives, enhancing manufacturing capabilities and capacity.
• **Debt Management:** ₹5.00 Crores is allocated for the full or partial repayment/prepayment of existing secured borrowings, strengthening the company's balance sheet.
• **Working Capital Support:** ₹43.15 Crores will be used to bolster the company's working capital requirements, ensuring smooth day-to-day operations and facilitating future growth.
• **General Corporate Purposes:** The remaining funds will be deployed for general corporate needs, providing flexibility for various strategic initiatives.

**Strategic Assessment: SWOT Analysis for Anlon Healthcare**

A thorough evaluation of Anlon Healthcare's internal and external factors can provide a balanced perspective for potential investors.

**Strengths:**

• **Diverse Product Portfolio:** A strong pipeline of 65 commercialized products and many in pilot/laboratory stages ensures diversified revenue streams.
• **High Entry Barriers:** The pharmaceutical intermediates and API sector is characterized by strict regulatory approvals and long customer approval cycles, creating a competitive advantage.
• **Robust Quality Control:** In-house testing, quality control, and assurance facilities, coupled with a skilled team, ensure consistent product quality adhering to global standards.
• **Strong Financial Growth:** Impressive revenue and PAT growth in recent years highlight effective business strategies and increasing market demand.
• **Experienced Management:** Led by strong promoters and an experienced management team, providing stable leadership and strategic direction.

**Weaknesses:**

• **Regulatory Dependence:** Continuous dependence on obtaining and maintaining various global regulatory approvals for product expansion.
• **Capital Intensive Operations:** Manufacturing in the chemical and pharma sector requires significant capital expenditure for expansion and R&D.

**Opportunities:**

• **Growing Pharma Market:** The expanding global pharmaceutical and healthcare industries drive sustained demand for APIs and intermediates.
• **Expansion Initiatives:** Utilization of IPO proceeds for capital expenditure and working capital allows for significant business scaling and market penetration.
• **Custom Manufacturing:** The ability to offer custom chemical manufacturing can open doors to specialized markets and higher-margin projects.
• **New Product Development:** Ongoing R&D and new DMF filings for additional APIs like Ketoprofen and Dexketoprofen Trometamol present future growth avenues.

**Threats:**

• **Intense Competition:** The sector faces competition from both domestic and international players, which could impact pricing power and market share.
• **Regulatory Changes:** Evolving pharmaceutical regulations globally could introduce compliance challenges and affect operational costs.
• **Raw Material Volatility:** Fluctuations in the cost and availability of key raw materials can impact production costs and profit margins.
• **Technological Shifts:** Rapid advancements in chemical synthesis and manufacturing processes by competitors could necessitate continuous investment in technology.

**Issue Management: The Registrar's Role**

**Kfin Technologies Ltd.** has been appointed as the official registrar for the Anlon Healthcare IPO. The registrar plays a crucial role in managing the IPO process, including application processing, allotment finalization, and crediting shares to investor demat accounts.

**Connect with Anlon Healthcare**

For direct inquiries or further information about the company:

• **Address:** 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005
• **Phone:** +91 281 2562538
• **Email:** cs@anloncro.com

**Your Questions Answered: IPO FAQs**

Here are answers to some common questions regarding the Anlon Healthcare IPO:

• **What is the Anlon Healthcare IPO?**

  It's a main-board IPO of 1,33,00,000 equity shares, with a face value of ₹10, aggregating up to ₹121.03 Crores. The price per share ranges from ₹86 to ₹91, and the minimum bid quantity is 164 shares.

• **When does the Anlon Healthcare IPO open and close?**

  The IPO opens for subscription on August 26, 2025, and closes on August 29, 2025.

• **What is the lot size for Anlon Healthcare IPO?**

  The minimum lot size is 164 shares, requiring an investment of ₹14,924 at the upper price band.

• **How can one apply for the Anlon Healthcare IPO?**

  Applications can be made online using either the UPI (Unified Payments Interface) or ASBA (Applications Supported by Blocked Amount) payment methods. ASBA is typically available through your bank's net banking portal, while UPI applications are often offered by various broking platforms.

• **When is the Anlon Healthcare IPO allotment expected?**

  The finalization of the Basis of Allotment is tentatively scheduled for Monday, September 1, 2025. Allotted shares are expected to be credited to your demat account by Tuesday, September 2, 2025.

• **When is the tentative listing date for Anlon Healthcare IPO?**

  The shares are expected to list on the BSE and NSE on Wednesday, September 3, 2025.

**Conclusion: A Look Ahead for Anlon Healthcare**

Anlon Healthcare's upcoming IPO presents an opportunity for investors to engage with a growing player in the essential pharmaceutical intermediates and API sector. With a strong track record of financial growth, a diverse product portfolio, significant regulatory approvals, and clear objectives for utilizing the IPO proceeds, the company appears well-positioned for future expansion.

The funds raised are intended to strengthen manufacturing capabilities, reduce debt, and bolster working capital, all of which are crucial for sustained growth in a competitive industry. As with any investment, prospective investors are encouraged to conduct their own diligent research and consider their financial goals before participating in the offering. The pharmaceutical sector holds promise, and Anlon Healthcare aims to carve out a significant niche within it.